AVITA Medical

AVITA Medical is a producer of the RECELL system, a suspension of “Spray-On-Skin” that uses the patient’s own cell samples to treat thermal burns and thickness-related skin defects. RECELL helps stimulate healing and repigmentation around the applied area, and the company claims that this technology has helped reduce patient’s length of stay in healthcare settings by up to 47%. AVITA has several RECELL varietie, for different skin treatment-related uses, such as regenerating the epidermis, depositing new extracellular matrix proteins, and producing melanin to restore natural pigmentation. In June 2023, the company received FDA approval for the use of RECALL in the treatment of vitiligo and full-thickness skin defects.

AVITA is publicly traded on the Nasdaq under the ticker symbol “RCEL,” and on the Australian Stock Exchange under the symbol “AVH.”

As of May 2024, the company had four commercialized variants of its RECALL solution for the treatment of thermal burns with partial thickness, thermal burns with full-thickness, treatment of traumatic wounds, and the treatment of surgical wounds. AVITA has applied for regulatory approval for the above range of RECALL solutions. AVITA has also commercialized a RECALL solution for wound healing, which is targeting international distribution.

Key customers and partnerships

AVITA received approval for the distribution of its RECELL system in Japan and partnered with COSMOTEC, an M3 Group company, in February 2022. Through the partnership, COSMOTEC led the approval process and agreed to act as AVITA’s distribution partner.

In January 2024, the company entered a sales partnership with Stedical Scientific, Inc to market, sell, and distribute Stedical’s PermeaDerm products, including any future enhancements or modifications, within the US.